Prestige Consumer Healthcare Inc. short interest in 2026
In 2026, Prestige Consumer Healthcare Inc.'s disclosed short interest ran from 4.31% of shares outstanding on 15 Jan 2026 to 10.12% on 15 Sep 2026, a change of +5.81 percentage points. The year's high was 10.12% on 15 Sep 2026 and its low 4.25% on 13 Feb 2026, averaging 6.32% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.05 days on 31 Aug 2026. Full history: Prestige Consumer Healthcare Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 4.31% (15 Jan 2026)
- End of year
- 10.12% (15 Sep 2026)
- Change
- +5.81 pp
- High
- 10.12% (15 Sep 2026)
- Low
- 4.25% (13 Feb 2026)
- Average
- 6.32%
- Highest days to cover
- 11.05 (31 Aug 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 4.31% | 6.68 | |
| 30 Jan 2026 | 4.62% | 5.47 | |
| 13 Feb 2026 | 4.25% | 4.57 | 10-Q filed, results (8-K) |
| 27 Feb 2026 | 5.02% | 5.11 | |
| 13 Mar 2026 | 5.28% | 6.44 | |
| 31 Mar 2026 | 5.69% | 5.08 | |
| 15 Apr 2026 | 4.86% | 3.48 | |
| 30 Apr 2026 | 6.17% | 6.68 | |
| 15 May 2026 | 5.67% | 2.78 | results (8-K), 10-K filed |
| 29 May 2026 | 5.23% | 3.38 | |
| 15 Jun 2026 | 6.19% | 4.59 | |
| 30 Jun 2026 | 6.78% | 3.52 | |
| 15 Jul 2026 | 6.52% | 6.65 | |
| 31 Jul 2026 | 8.06% | 8.10 | |
| 14 Aug 2026 | 9.01% | 6.22 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 9.68% | 11.05 | |
| 15 Sep 2026 | 10.12% | 9.45 |
See also: Prestige Consumer Healthcare Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.